Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 11:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Equine Therapy Clear all
Terminated Not applicable Interventional

Study of PET Scans and Serotonin in Hot Flashes Treatment

NCT00249847
View directory record Official record
Conditions
Hot Flashes
Interventions
Paroxetine controlled-release, Conjugated equine estrogen
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Sep 25, 2026, 11:02 PM EDT
Completed Not applicable Interventional

Hippotherapy to Improve the Balance of Children With Movement Disorders

NCT01313325
View directory record Official record
Conditions
Neuromuscular Diseases, Cerebral Palsy, Down Syndrome, Autism, Developmental Coordination Disorder
Interventions
Hippotherapy
Other
Lead sponsor
Central Michigan University
Other
Eligibility
5 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Dansville, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 10, 2011 · Synced Sep 25, 2026, 11:02 PM EDT
Completed Phase 3 Interventional Results available

Emergency Treatment of Coral Snake Envenomation With Antivenom

NCT01337245
View directory record Official record
Conditions
Coral Snake Bite, Toxic Effect of Coral Snake Venom
Interventions
Snake (Micrurus) North American immune F(ab')2 Equine
Drug
Lead sponsor
University of Arizona
Other
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
5
States / cities
Tucson, Arizona • DeLand, Florida • Fort Myers, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Sep 25, 2026, 11:02 PM EDT
Completed Phase 3 Interventional

Comparison of Peripheral Blood Stem Cell Transplantation With Bone Marrow Transplantation for the Treatment of Serious Hematological Malignancies

NCT00275678
View directory record Official record
Conditions
Blood Stem Cell Transplant
Interventions
Blood stem cell versus bone marrow transplant
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 66 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 2, 2010 · Synced Sep 25, 2026, 11:02 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

NCT00801931
View directory record Official record
Conditions
Leukemia, Lymphoma, Neuroblastoma, Immunodeficiencies, Anemia
Interventions
Alemtuzumab, Total Body Irradiation, Melphalan, Busulfan, Phenytoin, Fludarabine, Cyclophosphamide, Horse Antithymocyte Globulin, Rabbit Antithymocyte Globulin, Thiotepa
Drug · Radiation
Lead sponsor
Columbia University
Other
Eligibility
Up to 30 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Sep 25, 2026, 11:02 PM EDT
Terminated Not applicable Interventional

Pilot Study Adapting EAT-PTSD for Anxious Youth

NCT05298397
View directory record Official record
Conditions
Anxiety Disorder of Childhood or Adolescence
Interventions
EAT-PTSD adapted for youth for anxiety
Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
13 Years to 17 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Sep 25, 2026, 11:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Physiological Mechanisms of Therapeutic Horseback Riding Intervention Effects in a Psychiatric Population of ASD Youth

NCT04606966
View directory record Official record
Conditions
Autism Spectrum Disorder, Mental Disorders
Interventions
Therapeutic Horseback Riding, Barn Activity, Hybrid
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Years to 17 Years
Enrollment
236 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
2
States / cities
Aurora, Colorado • Portland, Maine
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 25, 2026, 11:02 PM EDT
Completed Phase 2 Interventional Results available

Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC

NCT00923364
View directory record Official record
Conditions
MDS, Immunodeficiency, GATA2
Interventions
Cyclophosphamide (CTX, Cytoxan), Fludarabine(Fludara,Berlex Laboratories), Total Body Irradiation (TBI), Allogeneic Hematopoietic Stem Cell (HSC), Equine Anti-Thymocyte Globulin
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Sep 25, 2026, 11:02 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

A Study of Emapalumab for Pediatric Aplastic Anemia

NCT06430788
View directory record Official record
Conditions
Aplastic Anemia, Cytopenia, Hypocellular Marrow
Interventions
Emapalumab
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
0 Years to 25 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
6
States / cities
New York, New York • Cincinnati, Ohio • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 25, 2026, 11:02 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery

NCT01500135
View directory record Official record
Conditions
Bleeding
Interventions
TachoSil®, Surgicel® Original
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
37
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Sep 25, 2026, 11:02 PM EDT
Completed Phase 2 Interventional

POETRY: Study of Estrogen Replacement Therapy in Postmenopausal Women With Parkinson's Disease

NCT00234676
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Premarin ®
Drug
Lead sponsor
The Parkinson Study Group
Network
Eligibility
Up to 75 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
6
States / cities
Sunnyvale, California • Atlanta, Georgia • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2008 · Synced Sep 25, 2026, 11:02 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Kronos Early Estrogen Prevention Study (KEEPS)

NCT00154180
View directory record Official record
Conditions
Menopause, Arteriosclerosis
Interventions
Conjugated equine estrogens 0.45 mg/day, Transdermal estradiol, 50 mcg/day, Micronized progesterone, 200 mg/day x 12 d/month, CEE , progesterone, estradiol patch or placebo for each, CEE, progesterone, transdermal patch or the placebo
Drug
Lead sponsor
Kronos Longevity Research Institute
Other
Eligibility
42 Years to 58 Years · Female only
Enrollment
728 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
9
States / cities
Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2009 · Synced Sep 25, 2026, 11:02 PM EDT
Completed Not applicable Interventional Results available

Feasibility and Acceptability Off The Equus Effect

NCT04159506
View directory record Official record
Conditions
Social Skills, Emotional Dysfunction
Interventions
mindfulness, emotion didactics, interpersonal skills, experiential learning
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Sep 25, 2026, 11:02 PM EDT
Withdrawn Not applicable Interventional

The Mechanism of Action of Unite Biomatrix in Venous Leg Ulcers

NCT00953563
View directory record Official record
Conditions
Venous Leg Ulcers
Interventions
Unite Biomatrix
Device
Lead sponsor
Baxter Healthcare Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
San Diego, California • Miami, Florida • Warren, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Sep 25, 2026, 11:02 PM EDT
Completed Phase 2 Interventional Results available

Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia

NCT00260689
View directory record Official record
Conditions
Immunosuppresion, Thrombocytopenia, Pancytopenia, Neutropenia
Interventions
Anti-thymocyte globulin (rabbit), Anti-thymocyte globulin (horse), Cyclosporine, Alemtuzumab
Biological · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Sep 25, 2026, 11:02 PM EDT
Completed Not applicable Interventional

Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia

NCT02845596
View directory record Official record
Conditions
Severe Aplastic Anemia
Interventions
cyclosporine, Matched Unrelated Donor Hematopoietic Stem Cell Transplant, horse anti-thymocyte globulin (ATG), rabbit anti-thymocyte globulin (ATG), methotrexate, fludarabine, cyclophosphamide, low-dose total body irradiation (TBI), Immunosuppressive Therapy (IST)
Drug · Procedure · Radiation
Lead sponsor
Michael Pulsipher
Other
Eligibility
Up to 25 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
13
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 10, 2025 · Synced Sep 25, 2026, 11:02 PM EDT
Completed Not applicable Interventional

A Mixed Methods Investigation of Equine-assisted Occupational Therapy for Children With Autism

NCT03493347
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Equine-assisted Occupational Therapy
Behavioral
Lead sponsor
Colorado State University
Other
Eligibility
5 Years to 14 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Loveland, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Sep 25, 2026, 11:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating the Impact of Reining in Anxiety

NCT04825756
View directory record Official record
Conditions
Anxiety, Anxiety Disorder
Interventions
Manualized equine assisted therapy
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
6 Years to 17 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Sep 25, 2026, 11:02 PM EDT
Not listed Not applicable Interventional

Study: Effects of a Collaborative Occupational Therapy Interactive Vaulting

NCT04481334
View directory record Official record
Conditions
Executive Function, Social Interaction, Disability, Developmental
Interventions
Collaborative occupational therapy interactive vaulting group
Other
Lead sponsor
East Carolina University
Other
Eligibility
5 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Sep 25, 2026, 11:02 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia

NCT03025698
View directory record Official record
Conditions
Aplastic Anemia
Interventions
Eltrombopag, hATG, CsA
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 18 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
12
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 25, 2026, 11:02 PM EDT
Not yet recruiting Phase 2 Interventional

UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia

NCT07001254
View directory record Official record
Conditions
Aplastic Anemia
Interventions
Romiplostim, Immunosuppressive therapy (IST)
Drug
Lead sponsor
Anjali Sharathkumar
Other
Eligibility
2 Years to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 25, 2026, 11:02 PM EDT
Completed Phase 1 Interventional

Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma

NCT02472392
View directory record Official record
Conditions
EWINGS SARCOMA
Interventions
Rabbit anti-thymocyte globulin, Busulfan, Melphalan, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
University of Louisville
Other
Eligibility
Up to 30 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 25, 2026, 11:02 PM EDT
Recruiting Phase 2 Interventional

Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

NCT01624805
View directory record Official record
Conditions
Aplastic Anemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome
Interventions
Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, Methylprednisolone, Pegfilgrastim
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 25, 2026, 11:02 PM EDT
Recruiting Phase 2 Interventional Results available

Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)

NCT04304820
View directory record Official record
Conditions
Severe Aplastic Anemia
Interventions
Eltrombopag, Cyclosporine, Horse-Anti-thymocyte-Globulin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
3 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2033
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 25, 2026, 11:02 PM EDT